ORIGINAL ARTICLE. Therapeutic Effect of Sentinel Lymphadenectomy in T1 Breast Cancer
|
|
- Hector Lang
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Therapeutic Effect of Sentinel Lymphadenectomy in T1 Breast Cancer David W. Ollila, MD; Meghan B. Brennan, RN, BSN; Armando E. Giuliano, MD Objective: To evaluate whether the tumor status of the sentinel lymph node (SN) would alter the systemic adjuvant therapy administered to patients with T1 breast cancer. Design and Patients: Consecutive breast cancer patients (tumors 2 cm) who underwent successful sentinel lymphadenectomy. Main Outcome Measures: Metastatic tumor in the SN, primary tumor size, recommendations for systemic adjuvant therapy before and after histopathologic evaluation of the SN, and actual systemic adjuvant therapy received by the patient. Results: Of 142 total patients, 14 had T1a tumors; 35, ; and 93,. Recommendations for systemic adjuvant therapy were initially determined solely by primary tumor characteristics and menopausal status. These recommendations were compared with recommendations for systemic adjuvant therapy based on tumor characteristics, menopausal status, and SN status; and then were compared with actual systemic adjuvant therapy received by the patient. Among the 118 patients with T1a,, and favorable (positive estrogen or progesterone receptors and a low S-phase percentage with respect to DNA content) tumors, 15 (37.5%) of 40 premenopausal patients and 20 (25.6%) of 78 postmenopausal patients became candidates for chemotherapy when examination of the SN revealed axillary metastasis; chemotherapy was actually administered to all 15 premenopausal patients but to only 6 postmenopausal patients. In the remaining 24 patients with unfavorable tumors, SN status did not change the recommendation for chemotherapy but may have altered the choice of specific chemotherapeutic agents. Conclusions: Identification of tumor-involved SN may alter systemic adjuvant therapy in patients with T1a,, and favorable tumors and may potentially change the type or dose of chemotherapeutic agents given to patients with unfavorable tumors. Surgical axillary staging of the axilla remains an essential part of breast cancer management and should not be abandoned. Arch Surg. 1998;133: From the John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, Calif. FOLLOWING SURGICAL management of primary breast cancer, systemic adjuvant therapy is indicated for patients with axillary metastases but also is increasingly recommended for those without histological evidence of axillary node involvement. 1-3 Because of this trend to use systemic adjuvant therapy regardless of lymph node status and because of the direct relationship between the incidence of axillary metastasis and the size of the primary tumor, 4,5 recent reports have questioned the benefit of routine level I and II axillary lymph node dissection (ALND) in patients with T1 primary breast cancers, particularly T1a and lesions. 6,7 The National Institutes of Health Consensus Development Conference 8 on the treatment of early-stage breast cancer recommended levels I and II ALND for the prevention of axillary recurrence and for accurate staging. Axillary lymph node dissection improves regional control in patients with palpable 9,10 or nonpalpable 11 tumor-involved nodes, but its effect on survival remains controversial. It may prolong survival by removing metastatic disease or because more patients with lymph node metastases receive systemic adjuvant therapy. 12 However, patients without histologically involved nodes clearly do not derive a therapeutic benefit from ALND and must deal with the associated potential morbidity of the procedure Because routine ALND for all patients with T1 breast cancer is associated with potential morbidity and no realized therapeutic benefit in those without tumorinvolved lymph nodes, nonsurgical staging alternatives have been explored. Un- 647
2 PATIENTS AND METHODS Candidates for this study were patients undergoing operative management of potentially curable breast cancer at the John Wayne Cancer Institute from October 1,1991, through October 3,1995. Only clinically node-negative patients with histopathologically confirmed American Joint Committee on Cancer 24 T1 breast cancer were included. After signing informed consent forms, all patients underwent intraoperative lymphatic mapping with SLND, followed immediately by level I and II ALND. Patients who did not have a successful SLND were excluded. Our technique of intraoperative mapping and SLND for breast cancer has been described previously Each SN was examined by frozen and permanent section with hematoxylin-eosin staining. If no tumor was identified using hematoxylin-eosin, then a cytokeratin immunohistochemical stain was performed using an antibody cocktail (MAK-6, Ciba-Corning, Alameda, Calif) that binds to cytokeratins. The nonsentinel axillary lymph nodes were processed by routine surgical pathologic techniques for isolation of lymph nodes, and were examined only with hematoxylin-eosin. All patients were seen in consultation by at least 1 surgical oncologist (A.E.G.) and 1 medical oncologist. If a patient was ineligible or declined to participate in an adjuvant therapy trial, recommendations for systemic adjuvant therapy were made by the treating oncologist following the definitive breast cancer operation. For this study, we constructed an algorithm for determining systemic adjuvant therapy based solely on the patient s menopausal status and primary tumor characteristics (Figure). This algorithm was constructed from the following: University of California, Los Angeles Breast Center practice guidelines, 25 Eastern Cooperative Oncology Group (ECOG) Protocol 2188, recommendations from the National Institutes of Health Consensus Development Conference on the treatment of early-stage breast cancer, 8 results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-13, 26,27 and results from NS- ABP Protocol B The 1990 National Institutes of Health Consensus Development Conference recommended that women with T1a and tumors and no axillary metastases not receive systemic adjuvant therapy outside a clinical trial. 8 The NSABP Protocol B-14 reported a diseasefree survival advantage and a trend toward increased overall survival when women with tumor-negative axillary nodes and favorable primary tumors received tamoxifen treatment instead of placebo. 28 NSABP B-13 demonstrated a disease-free survival advantage and a trend toward increased overall survival following chemotherapy with methotrexate, fluorouracil, and leucovorin vs no chemotherapy in node-negative women with unfavorable tumors. 27 The recommendations derived from our primary tumor based systemic adjuvant treatment algorithm were then compared with SN-based systemic adjuvant treatment recommendations that included menopausal status, primary tumor characteristics, and tumor status of the SN. If the SN did not contain metastasis, the algorithm in the Figure was applicable. However, if the SN contained metastasis, chemotherapy was recommended for all premenopausal women and for all postmenopausal women without a prohibitive medical comorbidity. Finally, we compared algorithm-derived recommendations with the actual systemic adjuvant therapy received by the patient. fortunately, no radiographic technique possesses the sensitivity or specificity to be clinically reliable, 16 and none of the prognostic risk models based on clinical features and primary tumor characteristics have been validated in a prospective trial. The size of the primary tumor and the status of the axillary nodes remain the best predictors of survival. We previously reported the use of intraoperative lymphatic mapping, sentinel lymphadenectomy (SLND), and focused histopathological review of the SN for accurate staging of breast cancer. Given the recent trend to determine systemic adjuvant therapy without considering the tumor status of axillary lymph nodes, we examined whether the status of the SN is of practical value and alters the systemic adjuvant therapy for patients with T1 breast cancer. Our objective was to evaluate the clinical impact of a minimally invasive surgical axillary staging procedure on the systemic adjuvant therapy given to patients with T1 breast cancer. RESULTS The median age of the 142 patients eligible for study was 56.4 years (range, years). The size of the primary tumor as measured on histopathologic sectioning ranged from microinvasive (arbitrarily defined as 0.1 cm) to 2 cm in the greatest dimension (median, 1.15 cm). Following American Joint Committee on Cancer guidelines, 24 the distribution of tumors was 14 of type T1a ( 0.5 cm); 35, ( 0.5 cm but 1.0 cm); and 93, ( 1.0 cm but 2.0 cm). The histological status, hormonereceptor status, and flow cytometry results for the primary tumor are summarized in Table 1. Patients who had insufficient or inadequate tumor tissue for receptor assays or flow cytometry were considered to have favorable tumors. The mean number of SNs examined per patient was 1.8 (range, 1-7) (Table 2); the mean number of non-sns examined was 17.3 (range, 4-44). The use of both staining techniques identified 43 patients (30.3%) with SN metastases. Table 3 shows how recommendations for systemic adjuvant therapy changed with the identification of SN metastases. All 6 premenopausal women with T1a or tumors and SN metastases became candidates for and received systemic chemotherapy. All 9 premenopausal women with favorable lesions (positive for estrogen or progesterone receptors and a low S-phase percentage for DNA content) and SN metastases became candidates for and received systemic chemotherapy. Thus, 15 (37.5%) of the 40 premenopausal women with T1a,, or favorable tumors received a treatment they would not have received based only on primary tumor characteristics. Tumor involvement of the SN did not alter recommendation of chemotherapy as the adjuvant mo- 648
3 Premenopausal Patients T1 Breast Cancer Postmenopausal Patients Table 1. Primary Tumor Characteristics* Tumor Type T1a, No Treatment Favorable Hormonal Therapy Unfavorable Chemotherapy T1a, No Treatment dality for premenopausal patients with unfavorable tumors (negative for estrogen and progesterone receptors or an elevated S-phase percentage with respect to DNA content), but it may have altered the type or dose of chemotherapeutic agent in 6 (37.5%) of the 16 women. The 2 postmenopausal women with T1a or tumors and SN metastases were eligible for adjuvant chemotherapy but received tamoxifen. Eighteen postmenopausal women with favorable tumors and SN metastases were candidates for systemic adjuvant chemotherapy; however, only 6 patients actually received chemotherapy and the remaining 12 received tamoxifen. Thus, 20 (25.6%) of the 78 postmenopausal patients with T1a,, or favorable tumors were candidates for systemic adjuvant chemotherapy, but only 6 (30%) of the patients actually received the treatment while the others did not because of a preexisting prohibitive medical comorbidity, advanced patient age, or oncologist preference. The status of the SN did not alter therapeutic recommendations in postmenopausal women with unfavorable tumors. COMMENT Favorable Hormonal Therapy Unfavorable Chemotherapy Primary tumor based systemic adjuvant treatment algorithm. According to this treatment algorithm based on primary tumor characteristics, 8,25-28 patients with T1a and tumors would not receive systemic chemotherapy or hormonal therapy. Premenopausal women with favorable lesions (estrogen receptor positive or progesterone receptor positive, low S-phase percentage with respect to DNA content) would receive tamoxifen therapy, and premenopausal women with unfavorable tumors (estrogen receptor negative and progesterone receptor negative, high S-phase with respect to DNA content) would receive systemic adjuvant chemotherapy. Postmenopausal women with favorable cancers would receive tamoxifen therapy, whereas patients with unfavorable tumors would receive chemotherapy. Asterisk indicates If no prohibitive medical comorbidity exists. Cady et al 6 report a 13% incidence of axillary metastasis in patients with T1a and primary tumors and suggest that no axillary dissection is needed in patients with mammographically detected T1a or tumors. Silverstein et al 7 report only a 3% incidence of axillary metastases in T1a tumors and recommend no axillary dissection for patients with T1a tumors that demonstrate good prognostic features. However, review of the Surveillance, Epidemiology, and End Results (SEER) Program Registry 29 of more than 8000 T1 tumors shows a higher incidence of axillary metastasis: 19.6% for T1a tumors; 20.6%, ; and 33.1%,. Similarly, we previously reported a 15%, 15%, and 33% incidence of axillary metastases in T1a,, and tumors, respectively. 30 The SEER data and our own institutional data indicate that nonsurgical evaluation of the axilla T1a Total T1 (%) Median size, cm Histological finding Invasive ductal (87.3) Invasive lobular (9.2) Special subtypes (3.5) Receptor status Estrogen Positive (78.2) Negative (19.0) Insufficient material (2.8) Progesterone Positive (65.5) Negative (30.3) Insufficient material (4.2) DNA content Diploid (48.6) Aneuploid (40.9) Insufficient material (10.6) Proliferative index Low (57.0) High (21.8) Insufficient material (21.1) *Values are expressed as number of tumors with each characteristic, unless otherwise specified. Table 2. Results of Sentinel Lymphadenectomy* T1a (n = 14) Stage of Cancer (n = 35) (n = 93) Mean No. SNs examined (range) 1.6 (1-3) 1.7 (1-5) 1.8 (1-7) Tumor-positive SNs HE stain, No. of tumors detected Macrometastasis Micrometastasis IHC stain, No. of tumors detected *SN indicates sentinel node; HE, hematoxylin-eosin; IHC, cytokeratin immunohistochemical. would understage 15% to 20% of the patients with T1a or tumors. In the present study, tumor involvement of the SN had a significant effect on the recommendations for systemic adjuvant therapy administered to premenopausal patients with T1 breast cancers, compared with recommendations for systemic adjuvant therapy based on the primary tumor. Prior to SN examination, 40 patients (28.2%) would have received no systemic adjuvant treatment (for T1a or tumors) or adjuvant tamoxifen alone (for favorable tumors); detection of SN metastasis changed the recommendations for systemic adjuvant therapy in 15 (37.5%) of these patients. The potential benefit of systemic adjuvant chemotherapy is highest in premenopausal women with axillary metastases, 31 and accurate axillary staging is essential to avoid overtreatment (if the axilla is assumed to harbor metastasis) or undertreatment (if the nodes are assumed to be free of tumor). 649
4 Table 3. Systemic Adjuvant Therapy in 21 Premenopausal Patients and 22 Postmenopausal Patients With Sentinel Node Metastases Tumor-Based SN-Based Actual Tumor Type No. of Patients* C H C H C H Premenopausal Patients T1a 2/ (29) 0 2 (29) 0 4/ (36) 0 4 (36) 0 Favorable 9/ (41) 0 9 (41) 0 Unfavorable 6/ Postmenopausal Patients T1a 0/ / (8) (8) Favorable 18/ (39) 0 6 (13) 12 Unfavorable 2/ *Number of patients with sentinel node metastases/total number of patients. C indicates chemotherapy; H, hormonal. Systemic adjuvant therapy based solely on the primary tumor characteristics. Systemic adjuvant therapy based on primary tumor characteristics and tumor status of sentinel node. Systemic adjuvant therapy actually received by the patient. Values in parentheses indicate percent change from tumor-based systematic adjuvant therapy. Type of Adjuvant Therapy In our group of postmenopausal patients, 20 (25.6%) of 78 women with T1a,, or favorable tumors were candidates for systemic adjuvant chemotherapy based on metastatic tumor in the SN. The fact that only 6 (30.0%) of the 20 actually received chemotherapy underlines the tendency to avoid more aggressive systemic adjuvant therapy in postmenopausal women due to preexisting medical comorbidities, advanced chronologic and physiologic age, and/or oncologist preference. In our postmenopausal patients, controversy over the significance of axillary micrometastasis 32,33 detected by cytokeratin immunohistochemical staining may have discouraged more frequent use of adjuvant systemic chemotherapy. Patients with unfavorable tumors have a poorer prognosis than those with favorable tumors. The standard recommendation is systemic adjuvant chemotherapy regardless of lymph node status, providing there is no prohibitive medical comorbidity. The tumor status of the SN did not change recommendations for systemic adjuvant chemotherapy in this group of patients but it may have altered the selection of chemotherapeutic agents, particularly if completion ALND revealed multiple tumor-involved nodes. 34,35 Some medical oncologists might even consider high-dose chemotherapy with peripheral stem-cell support for patients with more than 10 involved nodes, 36 and some high-dose chemotherapy protocols are accepting patients with as few as 4 tumor-involved nodes. Thus, even patients with unfavorable tumors potentially could receive a different chemotherapy regimen based on identification of axillary metastasis. The clinical significance of axillary micrometastasis remains controversial, but the medical oncologists in our community consider micrometastatic SN involvement to be node-positive breast cancer. Thus, if the SN harbors tumor cells, all patients with T1a,, and favorable breast cancers potentially could receive an alternate systemic adjuvant therapy, whereas patients with unfavorable lesions might receive an alternate chemotherapeutic regimen. We recommend SLND to provide an axillary specimen for focused histopathologic examination. Except among those investigators who have demonstrated a high degree of accuracy with this technique, SLND should routinely be followed by completion level I and II ALND to ensure accurate axillary staging and effective regional control. Surgical staging of the axilla remains essential in the management of breast cancer and should not be abandoned. This study was supported by the Ben B. and Joyce E. Eisenberg Foundation, Los Angeles, Calif, and the Fashion Footwear Association of New York, NY. Presented at the 68th Annual Session of the Pacific Coast Surgical Association, Napa, Calif, February 16, Validating statistician for this study was Karen Qi, Statistical Coordinating Unit, John Wayne Cancer Institute. Reprints: Armando E. Giuliano, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA REFERENCES 1. Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in highrisk node-negative breast cancer. N Engl J Med. 1989;320: Fisher B, Redmond C, Wickerham L, et al. Systemic therapy in patients with nodenegative breast cancer. Ann Intern Med. 1989;111: Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and flu- 650
5 orouracil for treatment of node-negative breast cancer patients with estrogen receptor-negative tumors. J Clin Oncol. 1996;14: Koscielny S, Tubiana M, Le MG, et al. Breast cancer: relationship between the size of the primary tumor and probability of metastatic dissemination. Br J Cancer. 1984;49: Foster RS. The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin North Am. 1996;5: Cady B, Stone MD, Wayne J. New therapeutic possibilities in primary invasive breast cancer. Ann Surg. 1993;3: Silverstein MJ, Gierson ED, Waisovan JR, et al. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer. 1994;73: NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer. Bethesda; Maryland, June 18-21, J Natl Cancer Inst Monogr. 1992; 11: Ruffin WK, Stacey-Clear A, Younger J, Hoover HC. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg. 1995;180: Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer. 1995;76: Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg. 1987;122: Cabanes PA, Salmon RJ, Vilcoq JR, et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer: The Breast Carcinoma Collaborative Group of the Institut Curie. Lancet. 1992;339: Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol. 1993;11: Vecht CJ, Van de Brand HJ, Wajer DJM. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve. Pain. 1989;38: Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1985;12: Kelley MC, Giuliano AE. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. In: Bland KI, Copeland EM, eds. The Breast: Comprehensive Management of Benign and Malignant Diseases. Vol 2. Philadelphia, Pa: WB Saunders Co. In press. 17. Chada M, Chabon AD, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1 breast cancer. Cancer. 1994;73: Menard S, Bufalino R, Rilke F, et al. Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer. 1994;70: Ravdin PM, DeLaurentiis M, Vendley T, Clark GM. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst. 1994;86: Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220: Giuliano AE, Dale PS, Turner RR. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222: Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15: Turner RT, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel node hypothesis for breast carcinoma. Ann Surg. 1997;226: American Joint Committee on Cancer. Manual for Staging of Cancer. 4th ed. Philadelphia, Pa: JB Lippincott Co; Love SM, McGuigan KA, Chap L. The Revlon/UCLA Breast Center practice guidelines for the treatment of breast disease. Cancer J. 1996;2: Fisher B, Redmond C, Dimtrov NV, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-negative tumor. N Engl J Med. 1989;320: Fisher B, Dignam J, Mamounas EP, et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors. J Clin Oncol. 1996;14: Fisher B, Constantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med. 1989;320: Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63: Giuliano AE, Barth AM, Spivack B, et al. Incidence and predictors of axillary metastasis in T1 carcinoma of the breast. J Am Coll Surg. 1996;3: Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 1992;339: 1-15, Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer. 1987;55: Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993;80: Abelhoff MD, Gray R, Tormey DC, et al. A randomized comparison of CMFPT versus CMFPTH/VATHT and maintenance versus no maintenance tamoxifen in premenopausal, node positive breast cancer patients, an ECOG study. Proc Am Soc Clin Oncol. 1991;10: Bonnadonna G, Valagussa P, Zambetti M. Sequential Adriamycin-CMF in the adjuvant treatment of breast cancer with more than 3 positive axillary nodes. Proc Am Soc Clin Oncol. 1992;11: Abelhoff MD, Beveridge RA, Donehower RC, et al. Sixteen-week dose-intense chemotherapy in adjuvant treatment of breast cancer. J Natl Cancer Inst. 1990; 82:
Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationPAPER. Long-term Outcome of Patients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer
ONLINE FIRST AER Long-term Outcome of atients Managed With Sentinel Lymph Node Biopsy Alone for Node-Negative Invasive Breast Cancer Nimmi S. Kapoor, MD; Myung-Shin Sim, DrH; Jennifer Lin, MD; Armando
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationORIGINAL ARTICLE. Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher-Echelon Nodes in the Axilla
ORIGINAL ARTICLE Characteristics of the Sentinel Lymph Node in Breast Cancer Predict Further Involvement of Higher-Echelon Nodes in the Axilla A Study to Evaluate the Need for Complete Axillary Lymph Node
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationEDITORIAL. Ann Surg Oncol (2011) 18: DOI /s
Ann Surg Oncol (2011) 18:2407 2412 DOI 10.1245/s10434-011-1593-7 EDITORIAL Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG)
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationPAPER. Predicting the Status of the Nonsentinel Axillary Nodes
Predicting the Status of the Nonsentinel Axillary Nodes A Multicenter Study PAPER Sandra L. Wong, MD; Michael J. Edwards, MD; Celia Chao, MD; Todd M. Tuttle, MD; R. Dirk Noyes, MD; Claudine Woo, MPH; Patricia
More informationTreatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy
Treatment Results and Prognostic Factors of Early Breast Cancer Treated with a Breast Conserving Operation and Radiotherapy Kyoung Ju Kim 1, Seung Jae Huh 1, Jung-Hyun Yang 2, Won Park 1, Seok Jin Nam
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationUpdates on management of the axilla in breast cancer the surgical point of view
Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of
More informationAt many centers in the United States and worldwide,
ORIGINAL ARTICLES A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Julia Park, MS, Jane V.
More informationApplicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery
Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationORIGINAL ARTICLE BREAST ONCOLOGY. Ann Surg Oncol (2010) 17: DOI /s x
Ann Surg Oncol (2010) 17:2690 2695 DOI 10.1245/s10434-010-1052-x ORIGINAL ARTICLE BREAST ONCOLOGY Discordance of Intraoperative Frozen Section Analysis with Definitive Histology of Sentinel Lymph Nodes
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationKey Words. Adjuvant therapy Breast cancer Taxanes Anthracyclines
The Oncologist Mayo Clinic Hematology/Oncology Reviews Adjuvant Therapy for Breast Cancer: Recommendations for Management Based on Consensus Review and Recent Clinical Trials BETTY A. MINCEY, a,b FRANCES
More informationSentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD
Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationTumor characteristics of breast cancer in predicting axillary lymph node metastasis
e-issn 1643-3750 DOI: 10.12659/MSM.890491 Received: 2014.02.05 Accepted: 2014.04.01 Published: 2014.07.07 Tumor characteristics of breast cancer in predicting axillary lymph node metastasis Authors Contribution:
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationRelevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:
Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management
More informationSentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner
Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated
More informationEvaluation of Immunohistochemistry and Multiple-Level Sectioning in Sentinel Lymph Nodes From Patients With Breast Cancer
Evaluation of Immunohistochemistry and Multiple-Level Sectioning in Sentinel Lymph Nodes From Patients With Breast Cancer Anjali S. Pargaonkar, MD; Robert S. Beissner, MD, PhD; Samuel Snyder, MD; V. O.
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2013.14.4.2657 Frozen Section Analysis of Sentinel Lymph Nodes for Detection of Breast Cancer Micro Metastasis RESEARCH ARTICLE Accuracy of Frozen Section Analysis of
More informationIs Sentinel Node Biopsy Practical?
Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer
More informationPROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT
PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationSentinel Node Biopsy and Clinical Decision Making
Sentinel Node Biopsy and Clinical Decision Making Monica Morrow, M.D. Chairman, Department of Surgical Oncology G. Willing Pepper Chair in Cancer Research The Evolving Role of Axillary Dissection Therapy
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationPractice of Axilla Surgery
Summer School of Breast Disease 2016 Practice of Axilla Surgery Axillary Lymph Node Dissection & Sentinel Lymph Node Biopsy 연세의대외과 박세호 Contents Anatomy of the axilla Axillary lymph node dissection (ALND)
More informationUltrasound or FNA for Predicting Node Positive in Breast Cancer
Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital
More informationManagement of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial
DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationWho Should Not Receive Chemotherapy? Data From American Databases and Trials
Who Should Not Receive Chemotherapy? Data From American Databases and Trials Monica Morrow, Helen Krontiras The demonstration of the effectiveness of chemotherapy in both premenopausal and postmenopausal
More informationAxillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer
EJSO 2002; 28: 481±489 doi:10.1053/ejso.2001.1239, available online at http://www.idealibrary.com on 1 Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationA Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer
The new england journal of medicine original article A Randomized Comparison of Sentinel-Node Biopsy with Routine Axillary Dissection in Breast Cancer Umberto Veronesi, M.D., Giovanni Paganelli, M.D.,
More informationSignificance of Micrometastases on the Survival of Women With T1 Breast Cancer
1234 Significance of Micrometastases on the Survival of Women With T1 Breast Cancer Douglas C. Maibenco, MD, PhD 1 George W. Dombi, PhD 2 Tsui Y. Kau, MS 3 Richard K. Severson, PhD 4 1 Surgical Specialists
More informationOriginal Study. Abstract. Introduction. Clinical Breast Cancer February
Outcomes of Clinically Node-Negative Breast Cancer Without Axillary Dissection: Can Preserved Axilla Be Safely Treated With Radiation After a Positive Sentinel Node Biopsy? Naoko Sanuki, 1 Atsuya Takeda,
More informationCHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD ( ) - A RETROSPECTIVE ANALYSIS
Archive of Oncology 2000;8(Suppl 1):7. SESSION 1 CHEMOTHERAPY OF BREAST CANCER IN SERBIA DURING THE FIVE-YEAR PERIOD (1995-2000) - A RETROSPECTIVE ANALYSIS 7 Archive of Oncology 2000;8(Suppl 1):8. 8 Extended
More informationThe Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer
The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein
More informationDuctal carcinoma in situ with microinvasion
ORIGINAL ARTICLE Microinvasive Breast Cancer and the Role of Sentinel Node Biopsy: An Institutional Experience and Review of the Literature Amber A. Guth, MD,* Cecilia Mercado, MD, Daniel F. Roses, MD,*
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationBreast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationConference Preview II
Conference Preview II CONFERENCE PREVIEW: JOINT CANCER CONFERENCE 2000 II. CLINICAL RESEARCH 1. RECENT ADVANCES IN THE TREATMENT AND OUTCOME OF LOCALLY ADVANCED RECTAL CANCER Edward M. Copeland III, MD
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationSentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy
ONCOLOGY REPORTS 15: 927-931, 2005 927 Sentinel node biopsy in breast cancer patients treated with neoadjuvant chemotherapy YOSUKE TANAKA 1, HIRONORI MAEDA 2, YASUHIRO OGAWA 3, AKIHITO NISHIOKA 3, SATOSHI
More informationSFMC Breast Cancer Site Study: 2011
SFMC Breast Cancer Site Study: 2011 Introduction Breast cancer is the most frequently diagnosed cancer among American women, except for skin cancers. It is the second leading cause of cancer death in women,
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationPreoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery
WESTERN SURGICAL ASSOCIATION ARTICLES Preoperative Axillary Ultrasound in Breast Cancer: Safely Avoiding Frozen Section of Sentinel Lymph Nodes in Breast-Conserving Surgery Irada Ibrahim-Zada, MD, PhD,
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationEvaluating the Z011 study and how local-regional therapy for early breast cancer may change
Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationBreast Cancer Survival According to Number of Nodes Removed
Annals of Surgical Oncology, 10(10):1152 1159 DOI: 10.1245/ASO.2003.03.073 Breast Cancer Survival According to Number of Nodes Removed David N. Krag, MD, FACS, and Richard M. Single, PhD Background: Results
More informationCopyright, 1995, by the Massachusetts Medical Society
Copyright, 99, by the Massachusetts Medical Society Volume 332 APRIL 6, 99 Number ADJUVANT CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE- POSITIVE BREAST CANCER The Results of Years of Follow-up
More informationSavitri Krishnamurthy, MD 1
EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY
More informationSentinel Lymph Node Detection in Early Carcinoma Breast: A Comparative Study Between Intralesional and Perilesional Dye Injection
Quest Journals Journal of Medical and Dental Science Research Volume 2~ Issue 11 (2015) pp: 11-15 ISSN(Online) : 2394-076X ISSN (Print):2394-0751 www.questjournals.org Research Paper Sentinel Lymph Node
More informationPrediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath
DOI 10.1007/s00268-014-2752-3 BRIEF ORIGINAL SCIENTIFIC REPORT Prediction of Lymph Node Involvement in Patients with Breast Tumors Measuring 3 5 cm in a Middle-Income Setting: the Role of CancerMath E.
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationDelayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
Annals of Oncology 11: 515-519, 2000. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled
More informationBreast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell
More informationRecurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationPAPER. Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer
PAPER Relapse and Morbidity in Patients Undergoing Sentinel Lymph Node Biopsy Alone or With Axillary Dissection for Breast Cancer D. Kay Blanchard, MD, PhD; John H. Donohue, MD; Carol Reynolds, MD; Clive
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationSentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy
The London Cancer Alliance West and South Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy Dimitri J Hadjiminas, MD, MPhil, FRCS (Consultant Breast & Endocrine Surgeon Imperial
More informationEffect of Occult Metastases on Survival in Node-Negative Breast Cancer
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Effect of Occult Metastases on Survival in Node-Negative Breast Cancer Donald L. Weaver, M.D., Takamaru Ashikaga, Ph.D., David N.
More informationOccult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up
VOLUME 26 NUMBER 11 APRIL 10 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationIs There a Need for Axillary Dissection in Breast Cancer?
225 Is There a Need for Axillary Dissection in Breast Cancer? Jason P. Wilson, MD a ; David Mattson, MD b ; and Stephen B. Edge, MD a ; Buffalo, New York Key Words Axillary node dissection, breast cancer,
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationFeasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients
Received: 21 April 2018 Revised: 14 May 2018 DOI: 10.1002/cam4.1606 Accepted: 14 May 2018 ORIGINAL RESEARCH Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel
More informationInes Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM
BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department
More informationORIGINAL ARTICLE. International Journal of Surgery
International Journal of Surgery (2013) 11(S1), S73 S78 Contents lists available at ScienceDirect International Journal of Surgery journal homepage: www.journal-surgery.net ORIGINAL ARTICLE Prognostic
More informationARTICLE IN PRESS. doi: /j.ijrobp METAPLASTIC CARCINOMA OF THE BREAST: A RETROSPECTIVE REVIEW
doi:10.1016/j.ijrobp.2005.08.024 Int. J. Radiation Oncology Biol. Phys., Vol. xx, No. x, pp. xxx, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front matter
More informationEvaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy
Evaluation of Pathologic Response in Breast Cancer Treated with Primary Systemic Therapy Eun Yoon Cho, MD, PhD Department of Pathology and Translational Genomics Samsung Medical Center Sungkyunkwan University
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationFactors Predicting Positive Axillary Lymph Nodes Metastasis in Primary Breast Cancer in Women
Factors Predicting Positive Axillary Lymph Nodes Metastasis in Primary Breast Cancer in Women General Surgeon, Dept. of Surgery, Ibn Sina College of Medicine, Iraqi University Abstract Objective: To predict
More informationSurgical Management of the Axilla
Surgical Management of the Axilla Jean-Francois Boileau, MD, MSc, FRCSC Surgical Oncologist, Montreal Jewish General Hospital Segal Cancer Centre Associate Member, Department of Oncology, McGill University
More information